NY bust: Medicaid patients' Rx drugs go to dealers

Dec 05, 2010 By CAROLYN THOMPSON , Associated Press

(AP) -- Police in western New York have charged 33 people so far in an investigation that shows a new kind of supplier in the illicit drug trade.

They say medical patients, including many who rely on Medicaid for prescriptions, have become a popular way to get drugs like to the street.

The patients see a doctor, or several doctors, and come away with prescriptions they sell to a dealer for as much as $1,000. Drug Enforcement Administration agents say the dealer can get $7,200 for the in that one bottle.

A federal report last year estimated 65,000 Medicaid beneficiaries in New York and four other states visited doctors in 2006 and 2007 to get prescriptions for the same type of controlled substances. The cost to was $63 million.

Explore further: FDA approves new drug for rare genetic disease

4.7 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

Medicaid policies vary widely for rheumatoid arthritis drugs

Nov 04, 2008

Patients with inflammatory diseases such as rheumatoid arthritis now have many more treatment options than in the past, including biologic disease-modifying antirheumatic drugs (DMARDs). These drugs, derived by modifying ...

11 people charged in Detroit painkiller scam

Jun 04, 2009

(AP) -- A federal indictment in Detroit says the government unwittingly paid more than $480,000 to a phony health-care business that was a front for acquiring and selling powerful painkillers as far away as Alabama.

Physicians click their way to better prescriptions

Mar 10, 2010

Is it time for all community-based doctors to turn to e-prescribing to cut down on the number of medication errors? According to Rainu Kaushal and colleagues from the Weill Cornell Medical College in New York, electronic ...

Recommended for you

Boxed warnings are common in novel therapeutics

12 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

14 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

15 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0